Lpath's Asonep fails to meet primary endpoint at Phase IIa; shares slide

25 March 2015

USA-based Lpath (Nasdaq: LPTN) says that its investigational therapy Asonep (sonepcizumab) did not meet the primary endpoint in a Phase IIa trial in renal cell carcinoma.

Lpath shares fell as much as 39% on the announcement, and were down 25% at $2.45 in after-hours trading yesterday.

The Phase IIa trial showed that Asonep did not meet the primary endpoint of significantly improving progression-free survival, but Dario Paggiarino, chief development officer at Lpath, said the results "suggest that in some patients with lower risk of disease progression based on prognostic factors, Asonep may produce prolonged disease stability for up to 20 months."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK